化学疗法与核素治疗多发骨转移癌疗效对比

目的：观察化学疗法及核素治疗骨转移癌的疗效。方法：对骨转移癌患者分别予以化学疗法及核素治疗，观察不同方法的疗效。结果：化学疗法治疗组中骨痛的缓解率分别是完全缓解（CR）0％，部分缓解（PR）8.3％；骨显像的变化是CR0％，PR7．7％，稳定0％；而核素治疗骨转移癌的疗效明确，骨痛的缓解率达到70．3％，骨显像异常浓聚点虽然CR为0％，但PR为45．9％，稳定为43．3％。结论：核素治疗骨转移疗效明确，其中^153Sm—EDTMP疗效更优于^89SrCl2。     

多点体温检测系统

本系统主要实现多点体温的检测和报警监控,使用DS18B20数字温度传感器,实现了对多个部位的体温连续高分辨率采集。以ATM89C51单片机为核心,兼有数据显示和体温监控报警功能,单总线系统结构,有较大检测范围。     

90Sr敷贴治疗寻常痤疮

笔者采用 90Sr敷贴器治疗各种类型的痤疮396例 ,取得了较好的疗效 ,报告如下。1　资料与方法1.1　一般资料　 396例均为我院门诊患者 ,年龄 14～ 4 5岁 ,其中男 2 2 1例 ,女 175例 ,分为丘疹型痤疮197例 ,脓疱型 16 8例 ,节型 18例 ,那囊肿型 3例 ,经前期 10例。1.2　治疗方法　采用90 Sr敷贴器 (由中国原子能科学研究院同位素所提供 ,其活度为I ,136MBq) ,行常规皮病敷贴方法治疗。治疗时用 2mm厚橡胶皮遮住正常皮肤 ,用剪刀按病灶大小、形状、剪去橡皮 ,暴露病变组织 ,敷贴器紧贴患处。90 Sr的照射剂量根据病程长短、痤疮的类型及年龄…     

Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer

93 patients with hormone refractory metastatic prostate cancer were entered on a prospective study to measure reduction in pain and changes in quality of life (QoL) after the administration of 150 MegaBequerel (MBq) Strontium-89 (Sr-89). QoL was assessed using a validated instrument, the Functional Living Index - Cancer (FLIC) questionnaire. Pain response was measured using the Radiation Therapy Oncology Group scoring system. Overall there was limited QoL improvement over 3 months following Sr-89. However, in the 53 patients (63%) achieving pain responses, QoL did significantly improve within 6 weeks of receiving Sr-89 compared to patients with stable or worsening bone pain, and this was independent of other parameters that might influence QoL outcomes, such as performance status, baseline PSA and extent of skeletal disease (P = 0.004). PSA 'response' occurred in 30 patients (37%) over 4 months after Sr-89. This did not appear to correlate with clinical improvement. This study supports the presumption that improvement in pain following Sr-89 is accompanied by better QoL. The lack of correlation of PSA response and clinical parameters indicates that in the palliative setting, PSA may not provide a useful surrogate for treatment outcome.     

人血清免疫球蛋白工作标准的制备与标定

本文报导混合浓缩人血清工作标准(89-1)的制备和用WHO相应参考标准血清标定出其中五类免疫球蛋白(Igs)及IgG4亚类含量。该制剂主要用于体外测定IgG、IgA、IgM的工作标准,也可供作体外测定IgD、IgE、IgG4的工作标准。混合前每份血清均无乙型肝炎表面抗原、转氨酶正常。定量分装为每安瓿0.5ml,经冷冻干燥后,4℃保存。参照国际参考标准血清67/97及67/37,分别以免疫单扩散法标定89-1中IgG、IgA、ISM含量;以酶联免疫吸附试验(ELISA)标定IgD、IgG4和IgE含量。其中IgG、IgG4、IgA、IgM含量,应用本室制备的相应单克隆抗体(McAb)标定,而IgD和IgE应用多克隆抗体(PcAb)进行标定。并用五剂量法及四剂量法分别计算Igs含量。     

The hederagenin saponin SMG-1 is a natural FMLP receptor inhibitor that suppresses human neutrophil activation

The pericarp of Sapindus mukorossi Gaertn is traditionally used as an expectorant in Japan, China, and Taiwan. Activated neutrophils produce high concentrations of the superoxide anion (O₂⁻) and elastase known to be involved in airway mucus hypersecretion. In the present study, the anti-inflammatory functions of hederagenin 3-O-(3,4-O-di-acetyl-α-l-arabinopyranoside)-(1→3)-α-l-rhamnopyranosyl-(1→2)-α-l-arabinopyranoside (SMG-1), a saponin isolated from S. mukorossi, and its underlying mechanisms were investigated in human neutrophils. SMG-1 potently and concentration-dependently inhibited O₂⁻ generation and elastase release in N-Formyl-Met-Leu-Phe (FMLP)-activated human neutrophils. Furthermore, SMG-1 reduced membrane-associated p47^phox expression in FMLP-induced intact neutrophils, but did not alter subcellular NADPH oxidase activity in reconstituted systems. SMG-1 attenuated FMLP-induced increase of cytosolic calcium concentration and phosphorylation of p38 MAPK, ERK, JNK, and AKT. However, SMG-1 displayed no effect on cellular cAMP levels and activity of adenylate cyclase and phosphodiesterase. Significantly, receptor-binding analysis showed that SMG-1 inhibited FMLP binding to its receptor in a concentration-dependent manner. In contrast, neither phorbol myristate acetate-induced O₂⁻ generation and MAPKs activation nor thapsigargin-caused calcium mobilization was altered by SMG-1. Taken together, our results demonstrate that SMG-1 is a natural inhibitor of the FMLP receptor, which may have the potential to be developed into a useful new therapeutic agent for treating neutrophilic inflammatory diseases.     

骨瘤胶囊联合核素89Sr治疗骨转移瘤临床分析

目的 观察骨瘤胶囊联合核素⁸⁹Sr治疗骨转移瘤的临床疗效。方法 采用随机分组法,以中药骨瘤胶囊联合⁸⁹Sr及单纯⁸⁹Sr治疗骨转移瘤患者各50例,观察患者疼痛程度、骨质修复、外周血象及生存质量等情况。结果 治疗组与对照组止痛有效率分别为94.0%和76.0%(P<0.05;生存质量的提高稳定率分别为94.0%和74.0%(P<0.05);治疗后两组间转移病灶骨代谢情况及血液毒性反应均具有显著差异(P<0.05,P<0.01)。结论 ⁸⁹Sr联合骨瘤胶囊治疗骨转移瘤,可提高止痛作用及患者的生存质量,降低血液毒性反应,是一种疗效确切的联合治疗方法。